143 related articles for article (PubMed ID: 2654207)
1. Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol.
Norris MJ; Carlin MC; Ratz JL
J Am Acad Dermatol; 1989 Apr; 20(4):643-9. PubMed ID: 2654207
[TBL] [Abstract][Full Text] [Related]
2. Treatment of telangiectasia: comparison of sclerosing agents.
Carlin MC; Ratz JL
J Dermatol Surg Oncol; 1987 Nov; 13(11):1181-4. PubMed ID: 3312331
[TBL] [Abstract][Full Text] [Related]
3. 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up.
Moreno-Moraga J; Smarandache A; Pascu ML; Royo J; Trelles MA
Phlebology; 2014 Dec; 29(10):658-66. PubMed ID: 23989971
[TBL] [Abstract][Full Text] [Related]
4. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins.
Kern P; Ramelet AA; Wutschert R; Bounameaux H; Hayoz D
Dermatol Surg; 2004 Mar; 30(3):367-72; discussion 372. PubMed ID: 15008862
[TBL] [Abstract][Full Text] [Related]
5. Polidocanol Plus Glucose Versus Glucose Alone for the Treatment of Telangiectasias: Triple Blind, Randomised Controlled Trial (PG3T).
Bertanha M; Yoshida WB; Bueno de Camargo PA; Moura R; Reis de Paula D; Padovani CR; Sobreira ML
Eur J Vasc Endovasc Surg; 2021 Jan; 61(1):128-135. PubMed ID: 32778489
[TBL] [Abstract][Full Text] [Related]
6. The Australian polidocanol (aethoxysklerol) study. Results at 2 years.
Conrad P; Malouf GM; Stacey MC
Dermatol Surg; 1995 Apr; 21(4):334-6; discussion 337-8. PubMed ID: 7728486
[TBL] [Abstract][Full Text] [Related]
7. Sclerotherapy for leg telangiectasia--a blinded comparative trial of polidocanol and hypertonic saline.
McCoy S; Evans A; Spurrier N
Dermatol Surg; 1999 May; 25(5):381-5; discussion 385-6. PubMed ID: 10469077
[TBL] [Abstract][Full Text] [Related]
8. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline.
Peterson JD; Goldman MP; Weiss RA; Duffy DM; Fabi SG; Weiss MA; Guiha I
Dermatol Surg; 2012 Aug; 38(8):1322-30. PubMed ID: 22620717
[TBL] [Abstract][Full Text] [Related]
9. Polidocanol (aethoxysklerol) for sclerotherapy of superficial venules and telangiectasias.
Goldman PM
J Dermatol Surg Oncol; 1989 Feb; 15(2):204-9. PubMed ID: 2644330
[TBL] [Abstract][Full Text] [Related]
10. Nd:Yag laser combined with injection sclerotherapy in the treatment of reticular veins and telangiectasias (CLaCS method): A triple-blind randomized clinical trial comparing two sclerosing agents associated with same laser patterns.
Fonseca MM; Mocelin FJ; Grill MH; Gianesini S; Miyake K; Argenta R; Pereira AH
Phlebology; 2023 Apr; 38(3):165-171. PubMed ID: 36657386
[TBL] [Abstract][Full Text] [Related]
11. Sclerotherapy: a study comparing polidocanol in foam and liquid form.
Uncu H
Phlebology; 2010 Feb; 25(1):44-9. PubMed ID: 20118346
[TBL] [Abstract][Full Text] [Related]
12. Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol.
Weiss RA; Weiss MA
J Dermatol Surg Oncol; 1990 Sep; 16(9):800-4. PubMed ID: 2398199
[TBL] [Abstract][Full Text] [Related]
13. Skin hyperpigmentation after sclerotherapy with polidocanol: A systematic review.
Bossart S; Daneluzzi C; Cazzaniga S; Ramelet AA; Uthoff H; Seyed Jafari SM; Baumgartner M; Hunger RE; Heidemeyer K; Willenberg T
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):274-283. PubMed ID: 36196455
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of sodium tetradecyl sulfate and polidocanol as sclerosants for leg telangiectasia based on histological evaluation with clinical correlation.
Bush R; Bush P
Phlebology; 2017 Aug; 32(7):496-500. PubMed ID: 27738241
[TBL] [Abstract][Full Text] [Related]
15. Reply to 'Treatment of Essential Telangiectasia': Use of Polidocanol.
Reynolds O
J Am Acad Dermatol; 1990 Jan; 22(1):148. PubMed ID: 2298961
[No Abstract] [Full Text] [Related]
16. Postsclerotherapy hyperpigmentations. Chromated glycerin as a screen for patients at risk (a retrospective study).
Georgiev M
J Dermatol Surg Oncol; 1993 Jul; 19(7):649-52. PubMed ID: 8349903
[TBL] [Abstract][Full Text] [Related]
17. Venous lake of the lip treated with a sclerosing agent: report of two cases.
Kuo HW; Yang CH
Dermatol Surg; 2003 Apr; 29(4):425-8. PubMed ID: 12656828
[TBL] [Abstract][Full Text] [Related]
18. Polidocanol versus glucose in the treatment of telangiectasia of the lower limbs (PG3T): Protocol for a randomized, controlled clinical trial.
Bertanha M; Camargo PA; Moura R; Yoshida WB; Pimenta RE; Mariúba JV; Alcantara GP; de Paula DR; Sobreira ML
Medicine (Baltimore); 2016 Sep; 95(39):e4812. PubMed ID: 27684809
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial.
Rabe E; Otto J; Schliephake D; Pannier F
Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):238-45. PubMed ID: 17988905
[TBL] [Abstract][Full Text] [Related]
20. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence.
Todd KL; Wright DI;
Phlebology; 2014 Oct; 29(9):608-18. PubMed ID: 23864535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
